Search
AZD7442
go.drugbank.com/drugs/DB15787Investigational[L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]
CIGB 2020 Vaccine
go.drugbank.com/drugs/DB15808ExperimentalThe vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba.
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalIt is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.
Col-118
go.drugbank.com/drugs/DB05778InvestigationalIt is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.
Luvometinib
go.drugbank.com/drugs/DB21696InvestigationalLuvometinib is under investigation in clinical trial NCT07004075 (FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration).
Trapidil
go.drugbank.com/drugs/DB09283ExperimentalTrapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.
VLTS-589
go.drugbank.com/drugs/DB05430InvestigationalVLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Olenasufligene relduparvovec
go.drugbank.com/drugs/DB16264InvestigationalIt is an adeno-associated virus (AAV) vector that delivers a functional copy of the human SGSH gene.[L46671]